Ventripoint to extend, increase debenture financing

Executive Summary

• Ventripoint Diagnostics Ltd. seeks TSX‑V approval to extend its unsecured convertible debenture private placement to Nov 2, 2025 and increase the offering size from $500,000 to $560,000.
• Each unit consists of a $1,000 convertible debenture (10% interest, maturing Dec 31, 2027) plus 9,000 common share purchase warrants exercisable at $0.14 per share until Dec 31, 2027.
• Proceeds will fund sales and marketing, additional key personnel, and general working capital.

Key Details

• Extension Date: New deadline for the private placement is November 2, 2025 (previously earlier).
• Upsized Offering: Total target amount increased to $560,000 (up from $500,000).
• Unit Composition:
• One unsecured convertible debenture with a principal of $1,000.
• 9,000 common share purchase warrants per unit.
• Conversion Terms: Debentures convertible at any time before maturity at $0.11 per common share.
• Warrant Exercise Price: $0.14 per share; exercisable until December 31, 2027.
• Interest Rate: 10% per annum, payable semi‑annually in arrears, either in cash or by issuing shares at a 20‑day VWAP (subject to exchange approval).
• Maturity: December 31, 2027.
• Hold Period: Securities subject to a hold period of four months plus one day from closing date.
• Use of Proceeds: Finance operational costs related to sales and marketing, hire additional key personnel, and provide general working capital.
• Regulatory Approval: Offering remains contingent upon final approval by the TSX‑V.

Notable Quotes

(No executive quotes were provided in the release.)